Nature Communications (Jun 2021)
Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40
- Fan Yang,
- Zhenqiang He,
- Hao Duan,
- Duo Zhang,
- Juehui Li,
- Huijuan Yang,
- Jay F. Dorsey,
- Wei Zou,
- S. Ali Nabavizadeh,
- Stephen J. Bagley,
- Kalil Abdullah,
- Steven Brem,
- Lin Zhang,
- Xiaowei Xu,
- Katelyn T. Byrne,
- Robert H. Vonderheide,
- Yanqing Gong,
- Yi Fan
Affiliations
- Fan Yang
- Department of Radiation Oncology, University of Pennsylvania
- Zhenqiang He
- Department of Radiation Oncology, University of Pennsylvania
- Hao Duan
- Department of Radiation Oncology, University of Pennsylvania
- Duo Zhang
- Department of Radiation Oncology, University of Pennsylvania
- Juehui Li
- Department of Radiation Oncology, University of Pennsylvania
- Huijuan Yang
- Department of Radiation Oncology, University of Pennsylvania
- Jay F. Dorsey
- Department of Radiation Oncology, University of Pennsylvania
- Wei Zou
- Department of Radiation Oncology, University of Pennsylvania
- S. Ali Nabavizadeh
- Department of Radiology, University of Pennsylvania
- Stephen J. Bagley
- Abramson Cancer Center, University of Pennsylvania
- Kalil Abdullah
- Department of Neurosurgery, University of Pennsylvania
- Steven Brem
- Abramson Cancer Center, University of Pennsylvania
- Lin Zhang
- Department of Obstetrics and Gynecology, University of Pennsylvania
- Xiaowei Xu
- Department of Pathology and Laboratory Medicine, University of Pennsylvania
- Katelyn T. Byrne
- Abramson Cancer Center, University of Pennsylvania
- Robert H. Vonderheide
- Abramson Cancer Center, University of Pennsylvania
- Yanqing Gong
- Division of Human Genetics and Translational Medicine, Department of Medicine, University of Pennsylvania
- Yi Fan
- Department of Radiation Oncology, University of Pennsylvania
- DOI
- https://doi.org/10.1038/s41467-021-23832-3
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 15
Abstract
Glioblastomas are generally resistant to treatment with immune checkpoint inhibitors. Here the authors show that IL6 blockade, in combination with a CD40 agonist, overcomes macrophage-mediated immunosuppression and sensitizes glioblastoma to immune checkpoint blockade in preclinical models.
